<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461446</url>
  </required_header>
  <id_info>
    <org_study_id>P00013150</org_study_id>
    <secondary_id>1U54NS092090-01</secondary_id>
    <nct_id>NCT02461446</nct_id>
  </id_info>
  <brief_title>Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations</brief_title>
  <official_title>Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine cross-sectional and longitudinal medical,
      behavioral, and cognitive differences between PTEN ASD and other groups, as well as to
      identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In
      addition, this study will be creating and maintaining a biorepository and linked phenotypic
      database for PTEN ASD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autism spectrum disorders (ASD) are a set of neurodevelopmental disorders characterized by
      social communication/interaction impairments and restricted/repetitive behaviors. ASD
      associated with germline heterozygous PTEN mutations (PTEN ASD) is a genetically defined
      sub-group that, may be one of the more prevalent genetic disorders contributing to ASD
      (0.5-2%). The purpose of this research study is to carefully track the phenotypic and
      molecular characteristics of PTEN ASD and identify biomarkers for intervention studies.

      Individuals with PTEN ASD (ages 3 to 21), with macrocephalic ASD without a PTEN mutation
      (macro-ASD), healthy controls, and individuals with PTEN mutations without ASD (PTEN no-ASD)
      will be asked to participate in this study. Both males and females will be asked to
      participate. Additionally, to be eligible for study participation, individuals' primary
      communicative language must be English.

      The study involves 5 visits (3 on site visits) over the course of two years. Study visits
      will vary in length from about 4 hours to 6 hours. Study visits involve a physical exam,
      medical history questions and neuropsychological assessments and a blood draw done for
      laboratory studies. Individuals who have a clinically indicated MRI will have their scan
      extended for 15 minutes as part of this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in verbal abilities at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Verbal and non-verbal ability will be evaluated using Stanford Binet -5 or Mullen Scales of Early Learning (MSEL) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in communication ability at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Communication ability will be evaluated using composite score of the Peabody Picture Vocabulary Test (PPVT-4), Expressive Vocabulary Test (EVT-2), and the Children's Communication Checklist (CCC-2) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in verbal abilities at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Verbal and non-verbal ability will be evaluated using Stanford Binet 5 or Mullen Scales of Early Learning (MSEL) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in working memory at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Working memory will be evaluated using the Stanford Binet 5 at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in processing speed at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Processing Speed will be measured using the Processing Speed Index from the Weschler Intelligence Scales at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visual perception at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Visual perception will be measured using the Beery Developmental Test of Visuomotor Integration (VMI) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in motor functioning at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Motor functioning will be evaluated using the Purdue Pegboard (Pegs) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in working memory at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Working memory will be evaluated using the Stanford Binet 5 at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in processing speed at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Processing Speed will be measured using the Processing Speed Index from the Weschler Intelligence Scales at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visual perception at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Visual perception will be measured using the Beery Developmental Test of Visuomotor Integration (VMI) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in motor functioning at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Motor functioning will be evaluated using the Purdue Pegboard (Pegs) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in communication ability at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Communication ability will be evaluated using composite score of the Peabody Picture Vocabulary Test (PPVT-4), Expressive Vocabulary Test (EVT-2), and the Children's Communication Checklist (CCC-2) at 24 months</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>PTEN</condition>
  <condition>ASD</condition>
  <condition>Autism</condition>
  <condition>Macrocephaly</condition>
  <condition>PTEN Hamartoma Tumor Syndrome</condition>
  <arm_group>
    <arm_group_label>PTEN ASD</arm_group_label>
    <description>PTEN participants with Autism Spectrum Disorder group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTEN no ASD</arm_group_label>
    <description>PTEN participants without Autism Spectrum Disorder group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTEN Macrocephaly</arm_group_label>
    <description>PTEN participants with Macrocephaly group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy control group</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood draw for future correlative studies in the PTEN Biorepository of the Developmental
      Synaptopathies Consortium.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        120 patients will be enrolled for this study, ages 3 to 21.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals ages 3 to 21 years old at the time of consent who have documentation of a
             clinical diagnosis of autism spectrum disorder diagnosis and/or a verified PTEN
             mutation from a medical or mental health professional for inclusion in the PTEN ASD,
             PTEN no-ASD or ASD macrocephaly groups.

          -  Macrocephaly (head circumference greater than or equal to 98th percentile) for
             inclusion in the ASD macrocephaly group.

          -  Youth ages 3-17 and adults age 18-21 who do not have an autism spectrum disorder or a
             PTEN mutation for inclusion in the control group.

          -  Consent from parents or guardians or an adult with or suspected of having an autism
             spectrum disorder that does not require a legal guardian or an adult who is the
             healthy sibling of an individual with an autism spectrum disorder.

          -  Youths who are able (some young or severely impaired participants may not be able to
             provide assent) will be asked to provide assent.

          -  Families with multiple children who meet the above inclusion criteria will be
             permitted to have as many children participate as they wish. A separate consent form
             will be filled out for each child enrolled in the study.

          -  Primary communicative language must be English

        Exclusion Criteria:

          -  Clinically significant medical disease that would prohibit participation in the study
             procedures.

          -  Individuals with contraindication to MRI will be excluded from the MRI portion of the
             study such as:

               1. Cardiac pacemaker.

               2. Intracranial aneurysm clips, metallic implants or external clips within 10 mm of
                  the head.

               3. Implanted metallic devices such as pumps or neuro-stimulator devices.

               4. Metallic foreign material within the orbits.

               5. Pregnancy.

               6. Claustrophobia.

          -  No history of significant brain lesions or pathology including:

               1. History of large vessel strokes, brain tumors or previous neurosurgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charis Eng, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajna Filip-Dhima, MS</last_name>
    <phone>617-919-7068</phone>
    <email>Rajna.Filip-Dhima@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dzung Maria Nguyen</last_name>
      <phone>310-794-5065</phone>
      <email>DzungNguyen@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Julian Martinez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Libove</last_name>
      <phone>650-736-1235</phone>
      <email>rlibove@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Hardan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Mischianti</last_name>
      <phone>617-919-3499</phone>
      <email>Sarah.Mischianti@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Sahin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Klingemier</last_name>
      <phone>216-448-6392</phone>
      <email>klingee@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlin Sesock</last_name>
      <phone>216-636-5535</phone>
      <email>sesockk@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Charis Eng, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Mustafa Sahin</investigator_full_name>
    <investigator_title>Assistant in NeurologyAssociate Professor of Neurology, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>germline heterozygous PTEN mutations</keyword>
  <keyword>MRI</keyword>
  <keyword>10q23.3</keyword>
  <keyword>ASD</keyword>
  <keyword>Autism</keyword>
  <keyword>Macrocephaly</keyword>
  <keyword>PTEN Hamartoma Tumor Syndrome</keyword>
  <keyword>PTEN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Hamartoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
    <mesh_term>Megalencephaly</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

